1
|
Arora A, Raffaele A, Agarwala S, Parigi GB, Manzoni F, Klersy C, Bhatnagar V. 1124 Is Delayed Presentation A Prognostic Factor for The Survival of Patients with Esophageal Atresia More Than Associated Anomalies? Comparison Between Different Social Realities. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Background
The aim is to evaluate if different social reality could represent a prognostic factor as associated anomalies affecting survival of neonates with esophageal atresia (EA).
Method
Retrospective analysis of records of neonates with EA with or without Tracheoesophageal Fistula (TEF) from January 2011 to September 2018 at Policlinico San Matteo Pavia, Italy(SMAT) and the All India Institute of Medical Sciences New Delhi, India (AIIMS).Survival was correlated with the presence of anomalies, different types and the number of organ systems involved.Age at presentation and birth weight were considered to find an association with mortality.
Results
Out of 180 patients,162 were from AIIMS and 18 from SMAT.The overall mortality was 28.85%, which occurred at AIIMS, being 0% at SMAT.83.33% at SMAT and 72.84% at AIIMS had associated anomalies.The mortality was 25% for neonates without an anomaly, being 26.15% for those with one (p > 0.05).No statistically significant correlation between outcome and associated anomalies was found.Instead, survival declines gradually as the age at presentation increases.
Conclusions
The presence of associated anomalies paradoxically does not affect the outcome because incidence of delayed presentation has a stronger effect than the presence of associated anomalies. Sensibilization is necessary to improve survival in EA neonates in developing countries, such as India.
Collapse
Affiliation(s)
- A Arora
- Università Degli Studi di Pavia, Pavia, Italy
| | - A Raffaele
- Università Degli Studi di Pavia, Pavia, Italy
| | - S Agarwala
- All India Institute of Medical Sciences, New Delhi, India
| | - G B Parigi
- Università Degli Studi di Pavia, Pavia, Italy
| | - F Manzoni
- Università Degli Studi di Pavia, Pavia, Italy
| | - C Klersy
- Università Degli Studi di Pavia, Pavia, Italy
| | - V Bhatnagar
- All India Institute of Medical Sciences, New Delhi, India
| |
Collapse
|
2
|
|
3
|
Agarwala S, Mata DA, Hafeez F. Accuracy of a convolutional neural network for dermatological diagnosis of tumours and skin lesions in a clinical setting. Clin Exp Dermatol 2021; 46:1310-1311. [PMID: 33864422 DOI: 10.1111/ced.14688] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Revised: 04/11/2021] [Accepted: 04/12/2021] [Indexed: 12/01/2022]
Affiliation(s)
- S Agarwala
- Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA
| | - D A Mata
- Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - F Hafeez
- Department of Dermatology, Temple School of Medicine, St Luke's University Health System, Bethlehem, PA, USA
| |
Collapse
|
4
|
Hatibaruah A, Rahman M, Agarwala S, Singh SA, Shi J, Gupta S, Paul P. Circular RNAs in cancer and diabetes. J Genet 2021; 100:21. [PMID: 34057150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Circular RNAs (circRNAs) are a class of noncoding RNA molecules formed by the back splicing process. Compared to linear mRNA molecules they are more stable. CircRNA acts as miRNA sponges, regulates translation, epigenetic alterations, etc. However, the most significant aspect of circRNAs has been its role in regulating the hallmark of cancer and diabetes mellitus. Several circRNAs are extensively expressed in individuals with cancer and diabetics. Dysregulated expression of various circRNAs plays a crucial part in the development of type 2 diabetes mellitus. In the present review, we present the current understanding of cricRNAs biogenesis, regulatory mechanisms, reviews of recent findings and circRNA as potential biomarker.
Collapse
Affiliation(s)
- Animesh Hatibaruah
- 1University of Science and Technology, Nongpoh, Meghalaya 793 101, India.
| | | | | | | | | | | | | |
Collapse
|
5
|
Patel S, Murthy R, Sheth R, Goldfarb P, Rice K, Lyon J, Lu G, Redstone E, Agarwala S, Rosemurgy A, Brown D, Wachter E. Abstract No. 509 Oncolytic immunotherapy of hepatic tumors with intralesional rose bengal disodium. J Vasc Interv Radiol 2020. [DOI: 10.1016/j.jvir.2019.12.570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
6
|
Agarwala S, Kale M, Kumar D, Swaroop R, Kumar A, Kumar Dhara A, Basu Thakur S, Sadhu A, Nandi D. Deep learning for screening of interstitial lung disease patterns in high-resolution CT images. Clin Radiol 2020; 75:481.e1-481.e8. [PMID: 32075744 DOI: 10.1016/j.crad.2020.01.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Accepted: 01/16/2020] [Indexed: 10/25/2022]
Abstract
AIM To develop a screening tool for the detection of interstitial lung disease (ILD) patterns using a deep-learning method. MATERIALS AND METHODS A fully convolutional network was used for semantic segmentation of several ILD patterns. Improved segmentation of ILD patterns was achieved using multi-scale feature extraction. Dilated convolution was used to maintain the resolution of feature maps and to enlarge the receptive field. The proposed method was evaluated on a publicly available ILD database (MedGIFT) and a private clinical research database. Several metrics, such as success rate, sensitivity, and false positives per section were used for quantitative evaluation of the proposed method. RESULTS Sections with fibrosis and emphysema were detected with a similar success rate and sensitivity for both databases but the performance of detection was lower for consolidation compared to fibrosis and emphysema. CONCLUSION Automatic identification of ILD patterns in a high-resolution computed tomography (CT) image was implemented using a deep-learning framework. Creation of a pre-trained model with natural images and subsequent transfer learning using a particular database gives acceptable results.
Collapse
Affiliation(s)
- S Agarwala
- Department of Computer Science and Engineering, National Institute of Technology Durgapur, Durgapur, 713209, India
| | - M Kale
- Department of Electronics and Electrical Communication Engineering, Indian Institute of Technology Kharagpur, Kharagpur, 721302, India
| | - D Kumar
- Department of Computer Science and Engineering, National Institute of Technology Durgapur, Durgapur, 713209, India
| | - R Swaroop
- Department of Computer Science and Engineering, National Institute of Technology Durgapur, Durgapur, 713209, India
| | - A Kumar
- School of Computer and Information Science, University of Hyderabad, Hyderabad, 500046, India
| | - A Kumar Dhara
- Department of Electrical Engineering, National Institute of Technology Durgapur, Durgapur, 713209, India.
| | - S Basu Thakur
- Department of Chest Medicine, Medical College Kolkata, 700073, India
| | - A Sadhu
- Department of Radiology, Medical College Kolkata, 700073, India
| | - D Nandi
- Department of Computer Science and Engineering, National Institute of Technology Durgapur, Durgapur, 713209, India
| |
Collapse
|
7
|
Algazi A, Bhatia S, Agarwala S, Molina M, Lewis K, Faries M, Fong L, Levine LP, Franco M, Oglesby A, Ballesteros-Merino C, Bifulco CB, Fox BA, Bannavong D, Talia R, Browning E, Le MH, Pierce RH, Gargosky S, Tsai KK, Twitty C, Daud AI. Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol 2020; 31:532-540. [PMID: 32147213 DOI: 10.1016/j.annonc.2019.12.008] [Citation(s) in RCA: 68] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 11/27/2019] [Accepted: 12/23/2019] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Interleukin 12 (IL-12) is a pivotal regulator of innate and adaptive immunity. We conducted a prospective open-label, phase II clinical trial of electroporated plasmid IL-12 in advanced melanoma patients (NCT01502293). PATIENTS AND METHODS Patients with stage III/IV melanoma were treated intratumorally with plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg/ml followed by electroporation (six pulses, 1500 V/cm) on days 1, 5, and 8 every 90 days in the main study and additional patients were treated in two alternative schedule exploration cohorts. Correlative analyses for programmed death-ligand 1 (PD-L1), flow cytometry to assess changes in immune cell subsets, and analysis of immune-related gene expression were carried out on pre- and post-treatment samples from study patients, as well as from additional patients treated during exploration of additional dosing schedules beyond the pre-specified protocol dosing schedule. Response was measured by study-specific criteria to maximize detection of latent and potentially transient immune responses in patients with multiple skin lesions and toxicities were graded by the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0). RESULTS The objective overall response rate was 35.7% in the main study (29.8% in all cohorts), with a complete response rate of 17.9% (10.6% in all cohorts). The median progression-free survival in the main study was 3.7 months while the median overall survival was not reached at a median follow up of 29.7 months. A total of 46% of patients in all cohorts with uninjected lesions experienced regression of at least one of these lesions and 25% had a net regression of all untreated lesions. Transcriptomic and immunohistochemistry analysis showed that immune activation and co-stimulatory transcripts were up-regulated but there was also increased adaptive immune resistance. CONCLUSIONS Intratumoral Tavo was well tolerated and led to systemic immune responses in advanced melanoma patients. While tumor regression and increased immune infiltration were observed in treated as well as untreated/distal lesions, adaptive immune resistance limited the response.
Collapse
Affiliation(s)
- A Algazi
- Department of Medicine, University of California, San Francisco, San Francisco, USA
| | - S Bhatia
- Department of Medicine, University of Washington, Seattle, USA
| | - S Agarwala
- St. Luke's Cancer Center, Bethlehem, USA
| | - M Molina
- Lakeland Health Medical Center, Lakeland, USA
| | - K Lewis
- University of Colorado Cancer Center - Anschutz, Denver, USA
| | - M Faries
- Providence John Wayne Cancer Institute, Santa Monica, USA
| | - L Fong
- Department of Medicine, University of California, San Francisco, San Francisco, USA
| | - L P Levine
- Department of Medicine, University of California, San Francisco, San Francisco, USA
| | - M Franco
- Department of Medicine, University of California, San Francisco, San Francisco, USA
| | - A Oglesby
- Department of Medicine, University of California, San Francisco, San Francisco, USA
| | - C Ballesteros-Merino
- Earle A. Chiles Research Institute at Providence Portland Medical Center, Portland, USA
| | - C B Bifulco
- Earle A. Chiles Research Institute at Providence Portland Medical Center, Portland, USA
| | - B A Fox
- Earle A. Chiles Research Institute at Providence Portland Medical Center, Portland, USA
| | - D Bannavong
- OncoSec Medical Incorporated, San Diego, USA
| | - R Talia
- OncoSec Medical Incorporated, San Diego, USA
| | - E Browning
- OncoSec Medical Incorporated, San Diego, USA
| | - M H Le
- OncoSec Medical Incorporated, San Diego, USA
| | - R H Pierce
- OncoSec Medical Incorporated, San Diego, USA
| | - S Gargosky
- OncoSec Medical Incorporated, San Diego, USA
| | - K K Tsai
- Department of Medicine, University of California, San Francisco, San Francisco, USA
| | - C Twitty
- OncoSec Medical Incorporated, San Diego, USA
| | - A I Daud
- Department of Medicine, University of California, San Francisco, San Francisco, USA.
| |
Collapse
|
8
|
Agarwala S, Vijayvargiya M, Mehmood M. Protection of trunnion during revision total hip arthroplasty. Ann R Coll Surg Engl 2019; 101:532-533. [PMID: 31155925 DOI: 10.1308/rcsann.2019.0084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- S Agarwala
- Department of Surgery, PD Hinduja Hospital Medical Research Centre, Mumbai, India
| | - M Vijayvargiya
- Department of Orthopedics, PD Hinduja Hospital and Medical Research Centre, Mumbai, India
| | - M Mehmood
- Department of Orthopedics, PD Hinduja Hospital and Medical Research Centre, Mumbai, India
| |
Collapse
|
9
|
Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer 2018; 104:201-209. [PMID: 30388700 DOI: 10.1016/j.ejca.2018.09.013] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2018] [Accepted: 09/12/2018] [Indexed: 12/19/2022]
Abstract
According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018. Data on licencing and reimbursement of medicines and the number of patient treated were correlated with the data on health expenditure per capita (HEPC), Mackenbach score of health policy performance, health technology assessment (HTA), ASCO and ESMO Magnitude of clinical benefit scale (ESMO MCBS) scores of clinical benefit and market price of medicines. Regression analysis for evaluation of correlation between the parameters was carried out using SPSS software. The estimated number of patients without access in surveyed countries was 13768. The recommended BRAFi + MEKi combination and anti-PD1 immunotherapy were fully reimbursed/covered in 19 of 34 (55.8%) and 17 of 34 (50%) countries, and combination anti-CTLA4+anti-PD1 in was fully covered in 6 of 34 (17.6%) countries. Median delay in reimbursement was 991 days, and it was in significant correlation with ESMO MCBS (p = 0.02), median market price (p = 0.001), HEPC and Mackenbach scores (p < 0.01). Price negotiations or managed entry agreements (MEAs) with national authorities were necessary for reimbursement. In conclusion, great discrepancy exists in metastatic melanoma treatment globally. Access to innovative medicines is in correlation with economic parameters as well as with healthcare system performance parameters. Patient-oriented drug development, market access and reimbursement pathways must be urgently found.
Collapse
Affiliation(s)
- L Kandolf Sekulovic
- Department of Dermatology, Faculty of Medicine, Military Medical Academy, Belgrade, Serbia.
| | - J Guo
- Department of Urology and Melanoma, Peking University Cancer Hospital & Institute, Beijing, PR China
| | - S Agarwala
- St. Luke's University Hospital and Temple University, Bethlehem, USA
| | - A Hauschild
- Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany
| | - G McArthur
- Divisions of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia
| | - G Cinat
- Médica Oncóloga Instituto de Oncología Angel Roffo, Universidad de Buenos Aires Fundación CIDEA, Buenos Aires, Argentina
| | - A Wainstein
- Institute of Post-graduation, Faculdade de Ciências Médicas de Minas Gerais (FCM-MG) - Belo Horizonte (MG), Brazil
| | - C Caglevic
- Medical Oncology Service, Oncology Department, Clinica Alemana Santiago, Faculty of Medicine Clinica Alemana-Universidad Del Desarrollo, Santiago, Chile
| | - P Lorigan
- Institute of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
| | - H Gogas
- 1(st)Department of Internal Medicine, Laiko Hospital and 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - M Alvarez
- Medico en Instituto Nacional de Cancerologia, Mexico City Area, Mexico
| | - R Duncombe
- Institute of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
| | - C Lebbe
- APHP Dermatology Department, University Paris 7 Diderot, INSERM U976, PARIS, France
| | - K Peris
- Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy
| | - P Rutkowski
- Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland
| | - A Stratigos
- 1(st)Department of Internal Medicine, Laiko Hospital and 1st Department of Dermatology-Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - A-M Forsea
- Carol Davila University of Medicine and Pharmacy, Elias University Hospital Bucharest, Romania
| | - L De La Cruz Merino
- Department of Clinical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain
| | | | - R Dummer
- UniversitätsSpital Zürich-Skin Cancer Center, University Hospital, Zürich, Switzerland
| | - C Hoeller
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - C Gorry
- National Centre for Pharmacoeconomics, Old Stone Building, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland
| | - L Bastholt
- Department of Oncology, Odense University Hospital, Denmark
| | - D Herceg
- Department of Oncology, University Hospital Zagreb, Croatia
| | - B Neyns
- Department of Medical Oncology, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium
| | - R Vieira
- Department of Dermatology, Medical Faculty, University of Coimbra, Portugal
| | - P Arenberger
- Department of Dermatovenereology, Charles University 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic
| | | | - N Babovic
- Institute of Oncology and Radiology of Serbia, Belgrade, Serbia
| | - M Banjin
- Department of Oncology, University Hospital Sarajevo, Bosnia and Herzegovina
| | - K Putnik
- North Estonia Medical Centre, Tallinn, Estonia
| | - V Todorovic
- Clinic for Oncology and Radiotherapy, Podgorica, Montenegro
| | - K Kirov
- Clinic of Oncodermatology, National Cancer Center, Sofia, Bulgaria
| | - J Ocvirk
- Institute of Oncology Ljubljana, Ljubljana, Slovenia
| | - A Zhukavets
- Belarusian Medical Academy of Postgraduate Education (BelMAPE), Minsk, Belarus
| | - A Ymeri
- University Hospital Mother Theresa, Tirana, Albania
| | - I Stojkovski
- University Clinic of Radiotherapy and Oncology, Skopje, Macedonia
| | - C Garbe
- Centre for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany
| |
Collapse
|
10
|
Olszanski A, Gonzalez R, Corrie P, Pavlick A, Middleton M, Lorigan P, Plummer R, Skaria S, Herbert C, Gore M, Agarwala S, Daud A, Zhang S, Bahamon B, Rangachari L, Hoberman E, Kneissl M, Rasco D. Phase I study of the investigational, oral pan-RAF kinase inhibitor TAK-580 (MLN2480) in patients with advanced solid tumors (ST) or melanoma (MEL): Final analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx367.043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
|
12
|
Ribas A, Gonzalez R, Drabick J, Kummar S, Agarwala S, Nemunaitis J, Coffman R, Berman C, Schmidt E, Chartash E, Guiducci C, Candia A, Janssen R. Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw378.21] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Anderson C, Allen B, Sun W, Lee C, Agarwala S, Venigalla M, Greenberg L, Adkins D, Chen Y, Zhen W, Mould D, Holmlund J, Brill J, Sonis S, Buatti J. Phase 1b/2a Trial of Superoxide (SO) Dismutase (SOD) Mimetic GC4419 to Reduce Chemoradiation Therapy–Induced Oral Mucositis (OM) in Patients With Oral Cavity or Oropharyngeal Carcinoma (OCC). Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2015.12.033] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Nataraj V, Bakhshi S, Khan S, Rastogi S, Agarwala S. 3442 Timing of relapse and Surgery post relapse is predictive of survival in relapsed osteosarcoma patients - an observational study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31915-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Iqbal N, Shukla NK, Deo SVS, Agarwala S, Sharma DN, Sharma MC, Bakhshi S. Prognostic factors affecting survival in metastatic soft tissue sarcoma: an analysis of 110 patients. Clin Transl Oncol 2015; 18:310-6. [DOI: 10.1007/s12094-015-1369-9] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Accepted: 07/20/2015] [Indexed: 12/27/2022]
|
16
|
Goldfarb P, Low R, Lyon J, Agarwala S, Rosemurgy A, Wachter E. P-116 Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
17
|
Biswas B, Rastogi S, Khan SA, Shukla NK, Deo SVS, Agarwala S, Mohanti BK, Sharma MC, Vishnubhatla S, Bakhshi S. Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol. J Surg Oncol 2014; 111:683-9. [PMID: 25557999 DOI: 10.1002/jso.23861] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Accepted: 11/14/2014] [Indexed: 12/12/2022]
Abstract
BACKGROUND Data on patients with localized Ewing sarcoma family of tumors (ESFT) who have received a uniform chemotherapy protocol are minimal. METHODS This is a single institutional review of patients with ESFT treated between June 2003 and November 2011. RESULTS 224/374 (60%) patients with ESFT presented with localized disease; median age was 15 years (range: 0.1-55). Ninety-nine patients underwent surgery of which 50 received adjuvant radiotherapy; 80 patients received radical radiotherapy following neoadjuvant chemotherapy. At median follow-up of 40.2 months (range: 1.3-129), 5-year EFS, OS, and local-control-rate, were 36.8 ± 3.6%, 52.4 ± 4.3%, and 63 ± 4.3%, respectively. In multivariate analysis, tumor diameter > 8 cm (P = 0.03), symptom duration > 4 months (P = 0.04), and WBC > 11 × 10(9) /L (P = 0.003) predicted inferior EFS; spine/abdomino-pelvic primary (P = 0.009) and WBC > 11 × 10(9) /L (P = 0.003) predicted inferior OS. Tumor size > 8 cm (P = 0.03) and radical radiotherapy as local treatment (P = 0.01) predicted inferior local-control-rate. CONCLUSION Prognostic hazard models for EFS and OS based on significant prognostic factors suggested that patients with combination of ESFT of spine/abdomino-pelvic region and baseline WBC > 11 × 10(9) /L had inferior OS (hazard ratio 4.44, P < 0.001) while patients with combination of ESFT with symptom duration > 4 months, tumor diameter > 8 m and baseline WBC > 11 × 10(9) /L had inferior EFS (hazard ratio 3.89, P = 0.002).
Collapse
Affiliation(s)
- Bivas Biswas
- Department of Medical Oncology, Dr. B. R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Iqbal N, Shukla N, Deo S, Agarwala S, Sharma M, Bakhshi S. Evaluation of Outcome and Prognostic Factors in Synovial Sarcoma: a Single Large Institutional Study of 139 Cases. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu354.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
19
|
Agarwala S, Thompson J, Smithers B, Ross M, Scoggins C, Coventry B, Neuhaus S, Minor D, Singer J, Wachter E. Subgroup Efficacy in Patients Receiving Intralesional Rose Bengal to All Existing Melanoma in Phase Ii Study Pv-10-Mm-02. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu344.36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Biswas B, Rastogi S, Khan SA, Shukla NK, Deo SVS, Agarwala S, Sharma DN, Thulkar S, Vishnubhatla S, Pathania S, Bakhshi S. Hypoalbuminaemia is an independent predictor of poor outcome in metastatic Ewing's sarcoma family of tumours: a single institutional experience of 150 cases treated with uniform chemotherapy protocol. Clin Oncol (R Coll Radiol) 2014; 26:722-9. [PMID: 24919857 DOI: 10.1016/j.clon.2014.05.006] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Revised: 03/28/2014] [Accepted: 05/12/2014] [Indexed: 01/30/2023]
Abstract
AIMS Data on metastatic Ewing's sarcoma family of tumours (ESFT) with uniform chemotherapy protocol are minimal. MATERIALS AND METHODS This was a single institutional patient review of patients treated between June 2003 and November 2011 and evaluated on an intent-to-treat analysis. All patients received uniform chemotherapy: neoadjuvant chemotherapy (NACT), surgery and/or radiotherapy as local treatment followed by adjuvant chemotherapy. Local treatment was offered if the patient achieved a complete response and/or a partial response at both the primary and the metastatic site. RESULTS In total, 150/374 (40%) ESFT patients were metastatic, with a median age of 15 years (range: 2-50); a tumour diameter of 10 cm (range: 1.8-26). Most common metastatic sites were lung only (53; 35%), bone only (35; 23%) and combined bone/lung (25; 17%). Twenty patients underwent surgery; 55 patients received radical radiotherapy after NACT. After a median follow-up of 26.1 months (range: 1.6-101.6), 5 year event-free survival (EFS), overall survival and local control rate (LCR) were 9.1 ± 3.3%, 16.9 ± 5.2% and 31.8 ± 7.9%, respectively. Univariate analysis showed serum albumin ≤3.4 g/dl (P < 0.001) to predict inferior EFS. Tumour size >8 cm (P = 0.05), haemoglobin ≤10 g/dl (P = 0.04), hypoalbuminaemia (P = 0.003) and radical radiotherapy as local treatment (P = 0.03) predicted inferior overall survival. No factor significantly predicted LCR, although age ≤15 years (P = 0.08) and radical radiotherapy as local treatment (P = 0.09) had a trend towards inferior LCR. Hypoalbuminaemia was the only prognostic factor to predict EFS on multivariate analysis. CONCLUSION This was the largest study of metastatic ESFT from Asia and identified a unique prognostic factor. In view of dismal prognosis with conventional chemotherapy in metastatic ESFT with hypoalbuminaemia, palliative intent therapy may be a potential therapeutic alternative for this subgroup of patients, especially in resource-challenged situations.
Collapse
Affiliation(s)
- B Biswas
- Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | - S Rastogi
- Department of Orthopedics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | - S A Khan
- Department of Orthopedics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | - N K Shukla
- Department of Surgical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | - S V S Deo
- Department of Surgical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | - S Agarwala
- Department of Pediatric Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | - D N Sharma
- Department of Radiotherapy, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | - S Thulkar
- Department of Radiodiagnosis, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | - S Vishnubhatla
- Department of Biostatistics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | - S Pathania
- Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
| | - S Bakhshi
- Department of Medical Oncology, Dr B.R. Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India.
| |
Collapse
|
21
|
Sugandhi N, Agarwala S, Bhatnagar V, Singh MK, Sharma R. Liver histology in choledochal cyst- pathological changes and response to surgery: the overlooked aspect? Pediatr Surg Int 2014; 30:205-11. [PMID: 24370791 DOI: 10.1007/s00383-013-3453-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Histological changes in the liver in cases of choledochal cyst are seldom reported. The severity of liver pathology has an impact on the presentation, course and prognosis of hepatobiliary lesions. This study aims to record the histological changes in the liver and response to surgery in patients with choledochal cyst and to correlate these with the clinical symptoms and recovery. MATERIALS AND METHODS All children <12 years diagnosed with choledochal cyst were evaluated clinically, radiologically and biochemically at presentation. Excision of the cyst with intra-operative liver biopsy was done. Liver biopsy was repeated after 6 months of surgery. Both the liver biopsies were compared objectively in terms of hepatocellular damage, cholestasis, parenchymal inflammation, bile duct inflammation, bile duct proliferation, portal fibrosis and central venous distension with appropriate statistical tests. Clinical presentation and recovery were correlated with grades of liver pathology. RESULTS Forty-six patients were included. Pathological damage was observed in all the livers preoperatively. Post-operatively, significant resolution of histological changes was seen in hepatocellular damage (p < 0.0001), parenchymal inflammation (p = 0.0001), cholestasis (p = 0.0003) and bile duct proliferation (p = 0.0001). Portal fibrosis did not resolve. Central venous distension worsened. Severity of damage correlated significantly with younger age, symptom severity, anomalous pancreatico-biliary junction (APBJ) and obstructive biliary clearance on Tc-99 HIDA scan. Post-operative bile duct proliferation, bile duct inflammation and portal fibrosis were associated with cholangitis, re-do surgery and obstructive Tc-99 HIDA scan clearance in the post-operative period. CONCLUSIONS All patients with choledochal cyst show pathological changes in liver of varying severity. More severe symptoms, younger age and APBJ are associated with higher degree of liver damage. Except portal fibrosis and central venous distension, all other pathological changes regress after surgery. Regression can be hindered by post-op cholangitis, obstructive biliary clearance and post-op IHBR dilatation.
Collapse
Affiliation(s)
- N Sugandhi
- Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India,
| | | | | | | | | |
Collapse
|
22
|
Kaul B, Kaur P, Tripathi M, Khadgawat R, Ammini AC, Agarwala S, Kaushal S, Dattagupta S. An unusual cause of reversible axonal neuropathy and hypertension in a 10-year-old girl. J Clin Neurosci 2012; 19:1196-7. [PMID: 22613486 DOI: 10.1016/j.jocn.2011.10.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2010] [Revised: 09/12/2011] [Accepted: 10/23/2011] [Indexed: 10/28/2022]
Abstract
A 10-year-old girl, who was referred with refractory epilepsy, had 1.5 years of episodic abnormal behavior. On examination, she also had hypertension and peripheral neuropathy. Hypoglycemia with correspondingly high insulin levels was documented during a confusional episode. MRI of the abdomen revealed an islet cell tumor in the body of the pancreas. One year after tumor excision, both the neuropathy and hypertension showed remarkable improvement. A final diagnosis of insulinoma with hypoglycemic axonal neuropathy and hypertension (reversed with tumor excision) was made. Insulinoma is the commonest cause of hyperinsulinemic hypoglycemia in adults, but is rare in childhood. To our knowledge, distal symmetrical motor-sensory axonal neuropathy has been described in only 40 patients, and hypertension has not been reported with insulinoma.
Collapse
Affiliation(s)
- B Kaul
- Department of Neurology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110 029, India.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Agarwala S, Lim ZH, Nicholson E, Ho GW. Probing the morphology-device relation of Fe₂O₃ nanostructures towards photovoltaic and sensing applications. Nanoscale 2012; 4:194-205. [PMID: 22075796 DOI: 10.1039/c1nr10856e] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
A lot of research on nanomaterials has been carried out in recent years. However, there is still a lack of nanostructures that have a combination of superior properties; both efficient electron transport and high surface area. Here, the authors have tried to develop hybrid α-Fe(2)O(3) flower-like morphology which exhibits both superior electron transport and high surface area. Intrigued by the unique properties of Fe(2)O(3) at the nanoscale and its abundance in nature, we have demonstrated a facile template-free solution based synthesis of hybrid α-Fe(2)O(3) comprising nanopetals nucleating radially from a 3D core. Due to its simplicity, the synthesis process can be easily reproduced and scaled up. We carried out in-depth studies on gas sensing and dye-sensitized solar cell (DSSC) device characterization so as to gain an understanding of how surface area and transport properties are affected by variation in morphology. The hybrid α-Fe(2)O(3) nanostructures are studied as potential candidates for gas sensors and for the first time as a working electrode for DSSC.
Collapse
Affiliation(s)
- S Agarwala
- Department of Electrical & Computer Engineering, National University of Singapore, Engineering Science Program, Blk EA, #06-10, 9 Engineering Drive 1, Singapore
| | | | | | | |
Collapse
|
24
|
Pinqpank J, Hughes M, Alexander H, Faries M, Zager J, Siskin G, Agarwala S, Whitman E, Nutting C, Ozkan O. 9304 ORAL Percutaneous Hepatic Perfusion (PHP) Vs. Best Alternative Care (BAC) for Patients (pts) With Melanoma Liver Metastases – Efficacy Update of the Phase 3 Trial (NCT00324727). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72513-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
25
|
Agarwala S, Peh CKN, Ho GW. Investigation of ionic conductivity and long-term stability of a LiI and KI coupled diphenylamine quasi-solid-state dye-sensitized solar cell. ACS Appl Mater Interfaces 2011; 3:2383-2391. [PMID: 21648469 DOI: 10.1021/am200296f] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
In this work, enhancement of ionic conductivity and long-term stability through the addition of diphenylamine (DPA) in poly(ethylene oxide) (PEO) is demonstrated. Potassium iodide (KI) is adopted as the crystal growth inhibitor, and DPA is used as a charge transport enhancer in the electrolyte. The modified electrolyte is used with titanium dioxide (TiO2) nanoparticles, which is systematically tuned to obtain high surface area. The dye-sensitized solar cell (DSSC) showed a photocurrent of 14 mAcm2 with a total conversion efficiency of 5.8% under one sun irradiation. DPA enhances the interaction of the TiO2 nanoparticle film and the I-/I3- electrolyte leading to high ionic conductivity (3.5 × 10-3 Scm-1), without compromising on the electrochemical and mechanical stability. Electrochemical impedance spectroscopy (EIS) studies show that electron transport and electron lifetime are enhanced in the DPA added electrolyte due to reduced sublimation of iodine. The most promising feature of the electrolyte is increased device stability with 89% of the overall efficiency preserved even after 40 days.
Collapse
Affiliation(s)
- S Agarwala
- Department of Electrical and Computer Engineering, National University of Singapore, 4 Engineering Drive, Singapore 117576
| | | | | |
Collapse
|
26
|
Affiliation(s)
- D D Pramanik
- All India Institute of Medical Sciences, Pediatric Surgery, New Delhi, India
| | | | | | | | | | | |
Collapse
|
27
|
Bedikian AY, DeConti RC, Conry R, Agarwala S, Papadopoulos N, Kim KB, Ernstoff M. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 2011; 22:787-793. [PMID: 20855467 PMCID: PMC4303777 DOI: 10.1093/annonc/mdq438] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2010] [Accepted: 07/06/2010] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Docosahexaenoic acid-paclitaxel (DHA-paclitaxel, Taxoprexin(®)) is made by covalently conjugating the essential fatty acid DHA to the paclitaxel molecule. Preclinical studies of DHA-paclitaxel have demonstrated increased activity relative to paclitaxel and the potential for an improved therapeutic ratio. In the present study, the efficacy and toxicity profiles of DHA-paclitaxel were compared with those of dacarbazine. METHODS In this study, 393 chemonaive patients with metastatic melanoma were randomly assigned to receive either DHA-paclitaxel at a starting dose of 900 mg/m(2) IV on day 1 every 3 weeks or dacarbazine at a starting dose of 1000 mg/m(2) IV on day 1 every 3 weeks. The primary end point of the study was the comparison of overall survival (OS). RESULTS No significant difference in OS was noted between patients in the DHA-paclitaxel and dacarbazine arms. Similarly, there were no significant differences in response rate, duration of response, time to progression, and time to treatment failure between the two drugs. Safety results of the two drugs were as predicted from prior studies. Myelosuppression was more common with DHA-paclitaxel. CONCLUSIONS DHA-paclitaxel was not superior to dacarbazine. We conclude that further studies with the drug on an every 3-week schedule in melanoma are not warranted.
Collapse
Affiliation(s)
- A Y Bedikian
- Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston.
| | - R C DeConti
- Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa
| | - R Conry
- Division of Hematology & Oncology, Kirkland Clinic at Acton Road, Birmingham
| | - S Agarwala
- Department of Hematology/Oncology, St Luke's Cancer Center, Bethlehem
| | - N Papadopoulos
- Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston
| | - K B Kim
- Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston
| | - M Ernstoff
- Department of Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, USA
| |
Collapse
|
28
|
Nayak A, Iyer VK, Agarwala S. The cytomorphologic spectrum of Wilms tumour on fine needle aspiration: a single institutional experience of 110 cases. Cytopathology 2011; 22:50-9. [DOI: 10.1111/j.1365-2303.2010.00741.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Abstract
BACKGROUND IGF2 is a tumor suppressor gene at locus 11p15. Many hepatoblastomas have loss of heterozygosity (LOH) at this locus. Earlier studies have not demonstrated any association between LOH and prognosis. Aim of the study was to evaluate the prognostic significance of LOH at 11p15.5 in hepatoblastomas. METHODS DNA was isolated from normal liver and tumor tissue in 20 patients with hepatoblastoma. PCR was performed and cases were classified as LOH present, absent or non-informative. Patients' follow-up data was analyzed using Fischer's exact test and Kaplan-Meier survival analysis for relapse-free survival (RFS) in relation to LOH. Ethical clearance was obtained from the institutional ethics board. RESULTS All cases were informative for at least one microsatellite marker used. 4 of the 20 cases (20%) had LOH at 11p15.5. One patient died in the immediate postoperative period. 5 of 19 patients relapsed (26%). Of 4 patients who had LOH, 3 (75%) relapsed, the time to relapse being 7, 7 and 9 months, respectively. Of the 15 cases without LOH, 2 (13.3%) relapsed. 4 patients had mixed epithelial and mesenchymal histology; 3 of them had LOH. The 2 groups with and without LOH were well matched. The RFS for patients with LOH (n=4) was 13% (mean survival time [MST]: 8.7 months; 95CI 6.7-10.7), while the RFS for cases without LOH (n=15) was 75% (MST: 100.7 months; 95CI 74.5-126.8). CONCLUSION Mixed epithelial and mesenchymal histology is more frequently associated with LOH on chromosome 11p15.5 than pure epithelial histology. LOH on chromosome 11p15.5 is associated with a significantly increased incidence of relapse and a significantly shorter relapse-free survival in patients with hepatoblastoma. The risk of relapse is higher and the RFS lower both in standard-risk and high-risk patients with hepatoblastoma if they demonstrate the presence of LOH at 11p15.5.
Collapse
Affiliation(s)
- S Chitragar
- All India Institute of Medical Sciences, Pathology, New Delhi, India
| | | | | | | | | | | |
Collapse
|
30
|
Sigamani E, Iyer VK, Agarwala S. Fine needle aspiration cytology of infantile haemangioendothelioma of the liver: a report of two cases. Cytopathology 2010; 21:398-402. [DOI: 10.1111/j.1365-2303.2010.00739.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
|
31
|
Gupta C, Iyer VK, Kaushal S, Agarwala S, Mathur SR. Fine needle aspiration cytology of undifferentiated embryonal sarcoma of the liver. Cytopathology 2010; 21:414-6. [DOI: 10.1111/j.1365-2303.2009.00732.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
32
|
Agarwala S, Kevin M, Wong ASW, Peh CKN, Thavasi V, Ho GW. Mesophase ordering of TiO2 film with high surface area and strong light harvesting for dye-sensitized solar cell. ACS Appl Mater Interfaces 2010; 2:1844-1850. [PMID: 20617836 DOI: 10.1021/am100421e] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Mesophase ordering and structuring are carried out to attain optimized pore morphology, high crystallinity, stable porous framework, and crack-free mesoporous titanium dioxide (TiO(2)) films. The pore structure (quasi-hexagonal and lamellar) can be controlled via the concentration of copolymer, resulting in two different types of micellar packing. The calcination temperature is also controlled to ensure a well-crystalline and stable porous framework. Finally, the synthesized mesoporous TiO(2) film is modified by adding P25 nanoparticles, which act as scattering centers and function as active binders to prevent formation of microcracks. Adding P25 nanoparticles into mesoporous structure helps to provide strong light-harvesting capability and large surface area for high -efficiency dye-sensitized solar cells (DSSC). The short-circuit photocurrent density (J(sc)) of the cell made from mixture of mesoporous TiO(2) and P25 nanoparticles displays a higher efficiency of approximately 6.5% compared to the other homogeneous films. A combination of factors such as increased surface area, introduction of light-scattering particles, and high crystallinity of the mesoporous films leads to enhanced cell performance.
Collapse
Affiliation(s)
- S Agarwala
- Department of Electrical and Computer Engineering, National University of Singapore, Singapore 117576
| | | | | | | | | | | |
Collapse
|
33
|
Abstract
The use of bisphosphonates in the treatment of avascular necrosis of the femoral head is an encouraging but relatively new option with most published data being derived from small trials with limited follow-up. We present a clinicoradiological analysis of 395 hips with avascular necrosis which were treated with oral alendronate for three years with a mean follow-up of four years (1 to 8). Our results show an improvement in the clinical function, a reduction in the rate of collapse and a decrease in the requirement for total hip replacement, compared with the findings of other studies in which no treatment was given. This improvement is particularly marked if the treatment is begun in the pre-collapse stages of the disease. Even in Ficat stage-III hips some benefit was obtained from treatment with alendronate by at least a delay in the need for total hip replacement.
Collapse
Affiliation(s)
- S. Agarwala
- P. D. Hinduja National Hospital and Medical Research Centre, Mahim, Mumbai 400016, India
| | - S. Shah
- P. D. Hinduja National Hospital and Medical Research Centre, Mahim, Mumbai 400016, India
| | - V. R. Joshi
- P. D. Hinduja National Hospital and Medical Research Centre, Mahim, Mumbai 400016, India
| |
Collapse
|
34
|
Abstract
PURPOSE To compare the results of staple versus locking compression plate fixation after closing wedge high tibial osteotomy. METHODS A group of 23 patients (24 knees) who underwent box high tibial osteotomy and staple fixation was compared with another group of 19 patients (22 knees) who underwent a similar procedure but with locking compression plate fixation. Both groups were followed up for 3 years. The range of movement, Hospital for Special Surgery (HSS) Knee Score, time to full weight bearing, incidence of delayed union, femorotibial angle, and stage of osteoarthritis were compared. RESULTS At 6 months after the operation, the median HSS score and the proportion of patients with excellent or good scores were significantly higher in the locking compression plate than the staple fixation group (76 vs 62, p=0.003; 75% vs 42%, p=0.0354), but not at one and 3 years. The range of movement was significantly greater in the locking compression plate fixation group in the short term (6 weeks, 3 and 6 months), but not after one year. The median time to full weight bearing was significantly shorter in the locking compression plate fixation group (86 vs 116 days, p<0.001). There were fewer delayed unions in the locking compression plate fixation group but not significantly (1 vs 5, p=0.198), possibly because of the small numbers involved. There was no difference, within the limits of measurement error, in the femorotibial angle or correction loss between the 2 groups. CONCLUSION Locking compression plate fixation obviates the use of plaster casts, enables early mobilisation and bone union, and reduces the numbers with delayed union and the time to full weight bearing. Longer-term studies are needed to evaluate its effect on revarisation and arthropathy.
Collapse
Affiliation(s)
- S Agarwala
- PD Hinduja National Hospital and Medical Research Centre, Mumbai, Maharashtra, India.
| | | |
Collapse
|
35
|
Gupta A, Swaroop C, Agarwala S, Bakhshi S. Randomized controlled trial comparing efficacy of oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low risk febrile neutropenia. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3336-42. [PMID: 17005814 PMCID: PMC1610067 DOI: 10.1128/aac.00461-06] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Mycobacterium tuberculosis is a concern in patients with human immunodeficiency virus (HIV) infection. Rifampin (RIF), an agent used against M. tuberculosis, is contraindicated with most HIV protease inhibitors. Atazanavir (ATV) has clinical efficacy comparable to a standard of care regimen in naive patients and, when dosed with low-dose ritonavir (RTV), also in treatment-experienced patients. We evaluated here the safety and pharmacokinetics of ATV, resulting from three regimens of ATV, RTV, and RIF in 71 healthy subjects. The pharmacokinetics for ATV and RTV were assessed after 6 and 10 days of dosing with ATV 400 mg (n = 53) and with ATV-RTV at 300 and 100 mg (ATV/RTV 300/100; n = 52), respectively. Steady-state pharmacokinetics for ATV, RTV, RIF, and desacetyl-rifampin (des-RIF) were measured after 10 days of dosing of ATV/RTV/RIF 300/100/600 (n = 17), ATV/RTV/RIF 300/200/600 (n = 17), or ATV/RTV/RIF 400/200/600 (n = 14). An RIF 600-alone arm was enrolled as a control group (n = 18). With ATV/RTV/RIF 400/200/600, ATV area under the concentration-time curve values were comparable, but the C(min) values were lower relative to ATV 400 alone. ATV exposures were substantially reduced for the other RIF-containing regimens relative to ATV 400 alone and for all regimens relative to ATV/RTV 300/100 alone. RIF and des-RIF exposures were 1.6- to 2.5-fold higher than with RIF 600 alone. The incidence of grade 3/4 alanine aminotransferase/aspartate aminotransferase values was limited to 1 subject each in both the ATV/RTV/RIF 300/200/600 and the ATV/RTV/RIF 400/200/600 treatments. Coadministration of ATV with RIF was safe and generally well tolerated. Since ATV exposures were reduced in all regimens, ATV and RIF should not be coadministered at the dosing regimens studied.
Collapse
Affiliation(s)
- D M Burger
- Department of Clinical Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
| | | | | | | | | | | |
Collapse
|
37
|
Abstract
OBJECTIVE To evaluate for the occurrence of occult NVD in children with anorectal malformations (ARM) using urodynamic evaluation. METHODS This prospective study was carried out on children with ARM prior to and following definitive procedure. Urodynamic studies were performed on the Phoenix Griffon machine (Albyn Medical) using Phoenix plus software. RESULT Nineteen children in the age range of 3 months to 156 months (mean = 19.2) were included in this study. Among these 19 children 13 underwent re-evaluation after definitive surgery for ARM. There were 11(57.9%) males and 8(42.1%) females. Of the 19 children 14 (73.7%) were cases of high anorectal malformation (HARM) and 5 (26.3%) were cases of low anorectal malformation (LARM). Baseline evaluation done in 19 children revealed seven urodynamic patterns: Normal capacity, compliant without uninhibited contractions (UIC) (21.1%); Normal capacity, compliant with UIC (5.3%); Normal capacity, poorly compliant without UIC (5.3%); Normal capacity, poorly compliant with UIC (10.5%); small capacity, compliant with UIC (5.3%); Small capacity, poorly compliant with UIC (26.3%) and large capacity, complaint with UIC (26.3%). Thirteen patients were evaluated post operatively also and in only 23% (3 of 13) no change in urodynamic pattern were observed. In the remaining 76.9% (10 of 13) some changes in urodynamics pattern were observed. The deleterious changes observed were appearance of UIC in 30.8% (4 of 13), decrease in the bladder capacity in 23% (3 of 13) and decrease in bladder compliance in 15.4% (2 of 13). CONCLUSION Only 9 of of the 19 patients had normal urodynamics pre-operatively and post-operatively 3 more patients worsened. Incidence of occult NVD is high in patients with ARM even in the absence of clinical and radiological evidence of vertebral or lower urinary tract abnormalities. Though there seems to be a high incidence of changes in the neurovesical functions of these patients following definitive corrective surgery for ARM only time will show whether this has any deleterious effect on the upper tracts.
Collapse
Affiliation(s)
- Arun Kumar
- Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India
| | | | | |
Collapse
|
38
|
Cooney MM, Savvides P, Agarwala S, Wang D, Flick S, Bergant S, Bhakta S, Lavertu P, Ortiz J, Remick S. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5580] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5580 Background: CA4P is the first tubulin-binding vascular disrupting agent tested in the clinic. Phase I studies were devoid of significant myelosuppression, DLT included cardiovascular side effects, and there was demonstrable activity in ATC (Cancer Res 2002; 62:3408; Clin Cancer Res 2004; 10:96). Methods: Patients with metastatic ATC, good performance status, normal ECG and cardiac function, and no prior therapy for disseminated disease were eligible for study. CA4P at a dose of 45 mg/m2 was administered as 10-minute IV infusion on days 1, 8 and 15 every 28 days (1 cycle) until progression of disease. Results: A total of 18 patients (pts) (11M/7F), median age 62 (range 40–71 yrs), received a total of 55.67 cycles of treatment. Therapy was well tolerated with mild to moderate nausea, vomiting, headache, and tumor pain (3 pts with grade 3) all of which essentially resolved within first 24 hrs. There was no clinically meaningful myelosuppression or cardiac toxicity. No objective responses were seen; 6 pts with stable disease and 12 pts progressed. Median progression free survival (PFS) was 7.4 wks (range 2–84+ wks); with 28% of pts progression free > 3.0 mos. (12.0+, 14.3, 15.3, 25.6 and 84.0+ wks). Pts without bulky disease tended to do better. Fourteen pts have died; 4 are alive; and 2 are alive and on-study at 12.0+ and 84.0+ wks. Median survival is on the order of approximately 20 wks. Conclusions: Approximately a quarter of patients treated with single-agent CA4P experience greater than 3 mos. freedom from progression. Combined modality strategies with CA4P and either chemotherapy and other targeted agents or with radiation are warranted. [Supported in part by a clinical grant from OXiGENE, Inc., Waltham, MA and NIH grant nos. M01 RR-00080]. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. M. Cooney
- Case Comprehensive Cancer Center, Cleveland, OH; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Josephine Ford Cancer Center, Detroit, MI
| | - P. Savvides
- Case Comprehensive Cancer Center, Cleveland, OH; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Josephine Ford Cancer Center, Detroit, MI
| | - S. Agarwala
- Case Comprehensive Cancer Center, Cleveland, OH; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Josephine Ford Cancer Center, Detroit, MI
| | - D. Wang
- Case Comprehensive Cancer Center, Cleveland, OH; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Josephine Ford Cancer Center, Detroit, MI
| | - S. Flick
- Case Comprehensive Cancer Center, Cleveland, OH; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Josephine Ford Cancer Center, Detroit, MI
| | - S. Bergant
- Case Comprehensive Cancer Center, Cleveland, OH; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Josephine Ford Cancer Center, Detroit, MI
| | - S. Bhakta
- Case Comprehensive Cancer Center, Cleveland, OH; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Josephine Ford Cancer Center, Detroit, MI
| | - P. Lavertu
- Case Comprehensive Cancer Center, Cleveland, OH; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Josephine Ford Cancer Center, Detroit, MI
| | - J. Ortiz
- Case Comprehensive Cancer Center, Cleveland, OH; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Josephine Ford Cancer Center, Detroit, MI
| | - S. Remick
- Case Comprehensive Cancer Center, Cleveland, OH; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Josephine Ford Cancer Center, Detroit, MI
| |
Collapse
|
39
|
Abstract
Urethral duplication is an uncommon congenital anomaly, not often reported, which may be partial or complete. Anorectal malformations are not as uncommon and they may be associated with a host of associated anomalies. However, the association of urethral duplication with anorectal malformation is rare; this report describes two such cases. In one case the intervening septum could be incised endoscopically and in the other case the duplicated urethra was excised.
Collapse
Affiliation(s)
- A K Singal
- Department of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi, India
| | | | | | | |
Collapse
|
40
|
Affiliation(s)
- A Nayak
- Department of Pathology, AIIMS, Ansari Nagar, New Delhi, India
| | | | | | | |
Collapse
|
41
|
Lad VS, Jain J, Agarwala S, Sinha VK, Khandekar JV, Agrawal NB, Khandeparkar JMS, Patwardhan A. Right Atrial Trans-Septal Approach for Left Atrial Myxomas—Nine-Year Experience. Heart Lung Circ 2006; 15:38-43. [PMID: 16473789 DOI: 10.1016/j.hlc.2005.06.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2004] [Revised: 04/15/2005] [Accepted: 06/16/2005] [Indexed: 11/16/2022]
Abstract
OBJECTIVE In this single-center study we reviewed our experience with left atrial myxomas occurring over the past 9 years. METHODS Sixty-three patients underwent excision of cardiac myxomas between 1995 and 2004. Of these, 56 patients (32 females and 24 males) had left atrial (LA) myxoma. The mean age was 37.80+12.97 years (range 3.5-67 years). Echocardiography was the only diagnostic evaluation done. The preferred approach for resection was right atrial trans-septal. Annual echocardiographic evaluation was undertaken following surgery. Follow-up is current and available in all the survivors (range 4 months-9 years). RESULTS Clinically 75% of the LA myxomas simulated mitral stenosis. The symptoms were present for 2-6 months before operation. Most (86%) LA myxomas were attached to the fossa ovalis. Few (14%) originated from the LA wall, mitral valve annulus and anterior mitral leaflet. One patient succumbed to low cardiac output and another died of massive embolic stroke following surgery. There were no late deaths. Two patients (3.7%) developed left hemiparesis after operation but recovered completely. There was one (1.9%) recurrence 3 years after surgery. Atrial fibrillation occurred in one patient. Mitral insufficiency which was seen in two (3.7%) patients prior to surgery subsided following excision of the tumor. Postoperatively 94% patients remained without symptoms. CONCLUSION Owing to the risk of valvular obstruction or embolization early surgery is indicated. Right atrial trans-septal approach is safe and easy. Most patients are asymptomatic following surgery. A yearly follow-up is essential.
Collapse
Affiliation(s)
- V S Lad
- PK Sen Department of Cardiovascular & Thoracic Surgery, KEM Hospital, Parel, Mumbai 400 012, India.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
OBJECTIVE To evaluate the incidence, types and the effect on outcome of associated anomalies in neonates with anorectal malformations (ARM). METHODS This retrospective study was carried out on all neonates with ARM admitted to the neonatal surgical intensive care unit (NSICU) from 1998 through 2003. RESULTS Of the 754 neonates admitted to the NSICU during the study period of 6 years, there were 124 (16.4%) neonates with anorectal malformations. Of these 110 were included in the study. 73 % were male and 27% female. 86% of these were high ARM (HARM) while only 14% were low ARM (LARM). Associated anomalies were seen in 68% of patients. The incidence was 72% for HARM and 50% for LARM. The major associated anomalies consisted of esophageal (13%), gastrointestinal (GIT) (11%), genitourinary (GUT) (32%), skeletal (26%), cardiac (33%) and miscellaneous 26%. The overall survival rate was 84% (82% for HARM and 94% for LARM). The survival among those with associated esophageal anomalies was 43%, GIT 67%, GUT 80%, cardiac 61%, skeletal 76% and miscellaneous 79% respectively. This difference in survival was significant only for those with esophageal (p=0.004) and cardiac anomalies (p=0.0026). The survival rates among those with one, two or more than two organ systems involved with associated anomalies were 88%, 82% and 58% respectively. This difference was significant only for more than two organ systems involvement (p=0.003). CONCLUSION Associated anomalies are common in neonates with ARM, the incidence being similar for HARM and LARM. The survival depends upon the number and severity of associated anomalies both in patients with LARM and HARM. Neonates with more number of organ systems involved have a poorer survival specially when associated with esophageal and cardiac anomalies. All neonates with ARM merit a meticulous search for associated anomalies so that the management can be tailored for each baby.
Collapse
Affiliation(s)
- A Kumar
- Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Anandaraja S, Kumar A, Agarwala S, Gulati GS, Bal CS, Kothari SS. Liver herniation into the pericardium: an unusual cause of massive pericardial effusion with intrapericardial mass in a neonate. Pediatr Cardiol 2005; 26:862-5. [PMID: 16088416 DOI: 10.1007/s00246-005-0966-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In neonates presenting with massive pericardial effusion and pericardial mass, liver herniation into the pericardium is a rare diagnosis. Echocardiogram and CT scan are useful investigations in the diagnosis of pericardial masses. Continuation of the mass with the liver with the same texture as the liver helps to make the diagnosis of intrapericardial herniation of liver. Correct diagnosis of this condition is important because the surgical approach needed for management of this condition is different from that used for other pericardial masses.
Collapse
Affiliation(s)
- S Anandaraja
- Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India
| | | | | | | | | | | |
Collapse
|
44
|
Abstract
AIMS In an era, in which valve bladder is recognised as perhaps the single most important determinant of long-term outcome in patients with posterior urethral valves (PUV), an insight into the etiopathogenesis and management of valve bladders is warranted. The present study was designed to evaluate bladder dysfunction in PUV and to assess the response to imipramine in these patients, both subjectively and objectively, by serial urodynamic studies (UDS). METHODS From 1998-2001, 30 patients with PUV who had documented bladder dysfunction on UDS were studied. Patients with non-compliant or unstable bladders were treated with imipramine (1.5 - 2 mg/kg). All the patients in the present study were 5 years or older and hence old enough to be toilet trained. Assessment of continence and side effects of the drug was done after 3 months and repeat UDS were done at 3-6 months, 1 and 2 years. RESULTS On the basis of initial treatment, the patients were divided into 2 groups; a fulguration group (n = 10, 33.3 %) and a vesicostomy group (n = 20, 66.6 %). Symptomatic voiding dysfunction was present in 27 of the 30 patients (90 %). Two patterns of urodynamic abnormalities were noted in the present study; 1) unstable bladders with single or multiple uninhibited contractions (18/30 patients, 60 %), and 2) small capacity, hypocompliant, hypertonic bladder (12/30 patients, 40 %). Post imipramine therapy significant symptomatic improvement was noted in 16/30 patients. On serial UDS, there was a 18-20 % increase in maximum cystometric capacity (MCC) and 30-35 % increase in pressure specific bladder volume (PSBV) following one year of imipramine therapy in 16/30 patients and 11/30 patients, respectively. 4 patients failed to show any improvement in MCC and PSBV with imipramine, they had been initially diverted with vesicostomy and later required augmentation cystoplasty. CONCLUSION Unstable bladders and those with marginal bladder capacity and compliance showed the best response to imipramine therapy. Fibrotic, small capacity, hypertonic bladders are less responsive to imipramine. However, a trial of imipramine therapy is still warranted in these patients, as only 4/12 (33.3 %) patients with fibrotic hypertonic bladders failed to show any response and ultimately required augmentation cystoplasty. Imipramine qualifies as an effective and cheap drug for valve bladders.
Collapse
Affiliation(s)
- A Puri
- Department of Paediatric Surgery, All India Institute of Medical Sciences, New Delhi 110029, India
| | | | | | | | | |
Collapse
|
45
|
Kumar R, Tripathi M, Chandrashekar N, Agarwala S, Kumar A, Dasan JB, Malhotra A. Diagnosis of ectopic gastric mucosa using 99Tcm-pertechnetate: spectrum of scintigraphic findings. Br J Radiol 2005; 78:714-20. [PMID: 16046423 DOI: 10.1259/bjr/16678420] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
We highlight the spectrum of scintigraphic findings likely to be encountered in patients with ectopic gastric mucosa with illustrative cases for each such finding. 11 children (aged 4 months to 120 months, all males) underwent (99)Tc(m)-pertechnetate scintigraphic evaluation for ectopic gastric mucosa. Functioning ectopic gastric mucosa was detected in Meckel's diverticulae in three patients, in small bowel duplications in four, in a gastric duplication in one, and in intrathoracic foregut duplication cysts in three. Ectopic functioning gastric mucosa in Meckel's diverticulum, and gastric duplication is visualized simultaneously with the stomach while in intestinal duplications tracer activity can be visualized in the dynamic sequence and even before gastric tracer visualization. In the three patients with intrathoracic duplication cysts, the functioning ectopic gastric mucosa was evident only in the delayed (99)Tc(m)-pertechnetate images, much later than the visualization of stomach activity. Therefore, acquisition of delayed images are useful when the initial images are equivocal or negative in children with intrathoracic foregut duplication cysts. In addition, we suggest a hypothesis of a possible mechanism for the uptake of pertechnetate in ectopic gastric mucosa in some patients with intrathoracic forget duplication cysts. In conclusion, a variety of scintigraphic patterns may be found in patients with ectopic gastric mucosa undergoing (99)Tc(m)-pertechnetate scintigraphy depending upon the location and size of the ectopic tissue.
Collapse
Affiliation(s)
- R Kumar
- Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
| | | | | | | | | | | | | |
Collapse
|
46
|
Agarwala S, Jain DK, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study: reply. Rheumatology (Oxford) 2005. [DOI: 10.1093/rheumatology/kei004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Sherman ML, Ryan C, Blackstein M, Mendelson D, Agarwala S, Dooley W, Dahl T, Demitri GD. Phase 1/2 study of STA-4783, a novel heat shock protein 70 (hsp70) inducer, in combination with paclitaxel in patients with soft tissue sarcomas (STS). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9069] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. L. Sherman
- Synta Pharmaceuticals Corp., Lexington, MA; Oregon Health and Science Univ, Portland, OR; Mount Sinai Hosp, Toronto, ON, Canada; Arizona Cancer Ctr, Scottsdale, AZ; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Dana-Farber Cancer Inst, Boston, MA
| | - C. Ryan
- Synta Pharmaceuticals Corp., Lexington, MA; Oregon Health and Science Univ, Portland, OR; Mount Sinai Hosp, Toronto, ON, Canada; Arizona Cancer Ctr, Scottsdale, AZ; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Dana-Farber Cancer Inst, Boston, MA
| | - M. Blackstein
- Synta Pharmaceuticals Corp., Lexington, MA; Oregon Health and Science Univ, Portland, OR; Mount Sinai Hosp, Toronto, ON, Canada; Arizona Cancer Ctr, Scottsdale, AZ; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Dana-Farber Cancer Inst, Boston, MA
| | - D. Mendelson
- Synta Pharmaceuticals Corp., Lexington, MA; Oregon Health and Science Univ, Portland, OR; Mount Sinai Hosp, Toronto, ON, Canada; Arizona Cancer Ctr, Scottsdale, AZ; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Dana-Farber Cancer Inst, Boston, MA
| | - S. Agarwala
- Synta Pharmaceuticals Corp., Lexington, MA; Oregon Health and Science Univ, Portland, OR; Mount Sinai Hosp, Toronto, ON, Canada; Arizona Cancer Ctr, Scottsdale, AZ; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Dana-Farber Cancer Inst, Boston, MA
| | - W. Dooley
- Synta Pharmaceuticals Corp., Lexington, MA; Oregon Health and Science Univ, Portland, OR; Mount Sinai Hosp, Toronto, ON, Canada; Arizona Cancer Ctr, Scottsdale, AZ; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Dana-Farber Cancer Inst, Boston, MA
| | - T. Dahl
- Synta Pharmaceuticals Corp., Lexington, MA; Oregon Health and Science Univ, Portland, OR; Mount Sinai Hosp, Toronto, ON, Canada; Arizona Cancer Ctr, Scottsdale, AZ; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Dana-Farber Cancer Inst, Boston, MA
| | - G. D. Demitri
- Synta Pharmaceuticals Corp., Lexington, MA; Oregon Health and Science Univ, Portland, OR; Mount Sinai Hosp, Toronto, ON, Canada; Arizona Cancer Ctr, Scottsdale, AZ; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Dana-Farber Cancer Inst, Boston, MA
| |
Collapse
|
48
|
Atkins MB, Sosman J, Agarwala S, Logan T, Clark J, Ernstoff M, Lawson D, Dutcher J, Weiss G, Urba W, Margolin K. A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7552] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. B. Atkins
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - J. Sosman
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - S. Agarwala
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - T. Logan
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - J. Clark
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - M. Ernstoff
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - D. Lawson
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - J. Dutcher
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - G. Weiss
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - W. Urba
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| | - K. Margolin
- Beth Israel Deaconess Medcl Ctr, Boston, MA; Vanderbilt Univ, Nashville, TN; Pittsburgh Cancer Institute, Pittsburgh, PA; Indiana Univ, Indianapolis, IN; Loyola Univ Medcl Ctr, Maywood, IL; Dartmouth Hitchcock Medcl Ctr, Hanover, NH; Emory, Atlanta, GA; Our Lady of Mercy, Bronx, NY; Univ of Texas San Antonio, San Antonio, TX; Chiles Cancer Ctr, Portland, OR; City of Hope Natl Cancer Ctr, Duarte, CA
| |
Collapse
|
49
|
Gogas H, Polyzos A, Tsoutsos D, Panagiotou P, Iconomou T, Papadopoulos S, Papadopoulos O, Agarwala S, Stavrinidis I, Fountzilas G. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. Gogas
- HeCOG Data Office, Athens, Greece; HeCOG Data Office, Athens, Greece
| | - A. Polyzos
- HeCOG Data Office, Athens, Greece; HeCOG Data Office, Athens, Greece
| | - D. Tsoutsos
- HeCOG Data Office, Athens, Greece; HeCOG Data Office, Athens, Greece
| | - P. Panagiotou
- HeCOG Data Office, Athens, Greece; HeCOG Data Office, Athens, Greece
| | - T. Iconomou
- HeCOG Data Office, Athens, Greece; HeCOG Data Office, Athens, Greece
| | - S. Papadopoulos
- HeCOG Data Office, Athens, Greece; HeCOG Data Office, Athens, Greece
| | - O. Papadopoulos
- HeCOG Data Office, Athens, Greece; HeCOG Data Office, Athens, Greece
| | - S. Agarwala
- HeCOG Data Office, Athens, Greece; HeCOG Data Office, Athens, Greece
| | - I. Stavrinidis
- HeCOG Data Office, Athens, Greece; HeCOG Data Office, Athens, Greece
| | - G. Fountzilas
- HeCOG Data Office, Athens, Greece; HeCOG Data Office, Athens, Greece
| |
Collapse
|
50
|
Moschos SJ, Edington HD, Rao UN, Jukic D, Shipe-Spotloe J, Land SR, Agarwala S, Kirkwood JM. High dose Interferon-α2b (HDI): Toxicity, response, and predictive markers in a neoadjuvant trial for regional lymph node metastatic melanoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7517] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. J. Moschos
- Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Pittsburgh Medcl Ctr, Pittsburgh, PA; Univ of Pittsburgh, Pittsburgh, PA
| | - H. D. Edington
- Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Pittsburgh Medcl Ctr, Pittsburgh, PA; Univ of Pittsburgh, Pittsburgh, PA
| | - U. N. Rao
- Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Pittsburgh Medcl Ctr, Pittsburgh, PA; Univ of Pittsburgh, Pittsburgh, PA
| | - D. Jukic
- Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Pittsburgh Medcl Ctr, Pittsburgh, PA; Univ of Pittsburgh, Pittsburgh, PA
| | - J. Shipe-Spotloe
- Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Pittsburgh Medcl Ctr, Pittsburgh, PA; Univ of Pittsburgh, Pittsburgh, PA
| | - S. R. Land
- Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Pittsburgh Medcl Ctr, Pittsburgh, PA; Univ of Pittsburgh, Pittsburgh, PA
| | - S. Agarwala
- Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Pittsburgh Medcl Ctr, Pittsburgh, PA; Univ of Pittsburgh, Pittsburgh, PA
| | - J. M. Kirkwood
- Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Pittsburgh Medcl Ctr, Pittsburgh, PA; Univ of Pittsburgh, Pittsburgh, PA
| |
Collapse
|